These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 34800542)
41. Oncogenic Boutin AT; Liao WT; Wang M; Hwang SS; Karpinets TV; Cheung H; Chu GC; Jiang S; Hu J; Chang K; Vilar E; Song X; Zhang J; Kopetz S; Futreal A; Wang YA; Kwong LN; DePinho RA Genes Dev; 2017 Feb; 31(4):370-382. PubMed ID: 28289141 [TBL] [Abstract][Full Text] [Related]
42. The Safe Soluble Compound Dehydroascorbic Acid Inhibits Various Upstream and Downstream Effectors of PI3K and KRAS Signaling Pathways in Undruggable Kalbkhani F; Pirnejad A; Sam S; Sam MR Nutr Cancer; 2021; 73(11-12):2654-2664. PubMed ID: 33283545 [TBL] [Abstract][Full Text] [Related]
43. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556 [TBL] [Abstract][Full Text] [Related]
44. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218 [TBL] [Abstract][Full Text] [Related]
45. Relationships among Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081 [TBL] [Abstract][Full Text] [Related]
46. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764 [TBL] [Abstract][Full Text] [Related]
49. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879 [TBL] [Abstract][Full Text] [Related]
50. PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer. Yin XK; Wang YL; Wang F; Feng WX; Bai SM; Zhao WW; Feng LL; Wei MB; Qin CL; Wang F; Chen ZL; Yi HJ; Huang Y; Xie PY; Kim T; Wang YN; Hou JW; Li CW; Liu Q; Fan XJ; Hung MC; Wan XB Oncogene; 2021 Feb; 40(7):1375-1389. PubMed ID: 33420374 [TBL] [Abstract][Full Text] [Related]
51. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Zhu G; Pei L; Xia H; Tang Q; Bi F Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312 [TBL] [Abstract][Full Text] [Related]
52. Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model. Tsunoda T; Ota T; Fujimoto T; Doi K; Tanaka Y; Yoshida Y; Ogawa M; Matsuzaki H; Hamabashiri M; Tyson DR; Kuroki M; Miyamoto S; Shirasawa S Mol Cancer; 2012 Jul; 11():46. PubMed ID: 22830422 [TBL] [Abstract][Full Text] [Related]
53. Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. Magnetta MJ; Ghodadra A; Lahti SJ; Xing M; Zhang D; Kim HS Abdom Radiol (NY); 2017 Feb; 42(2):451-459. PubMed ID: 27600383 [TBL] [Abstract][Full Text] [Related]
54. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. Amankwatia EB; Chakravarty P; Carey FA; Weidlich S; Steele RJ; Munro AJ; Wolf CR; Smith G Br J Cancer; 2015 Apr; 112(9):1480-90. PubMed ID: 25919696 [TBL] [Abstract][Full Text] [Related]
55. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. Hagman H; Frödin JE; Berglund Å; Sundberg J; Vestermark LW; Albertsson M; Fernebro E; Johnsson A Ann Oncol; 2016 Jan; 27(1):140-7. PubMed ID: 26483047 [TBL] [Abstract][Full Text] [Related]
56. COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS. Zhang Z; Fang C; Wang Y; Zhang J; Yu J; Zhang Y; Wang X; Zhong J Int J Oncol; 2018 Nov; 53(5):1869-1880. PubMed ID: 30132520 [TBL] [Abstract][Full Text] [Related]
57. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. Modest DP; Camaj P; Heinemann V; Schwarz B; Jung A; Laubender RP; Gamba S; Haertl C; Stintzing S; Primo S; Bruns CJ J Cancer Res Clin Oncol; 2013 Jun; 139(6):953-61. PubMed ID: 23455880 [TBL] [Abstract][Full Text] [Related]
58. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784 [TBL] [Abstract][Full Text] [Related]
59. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598 [TBL] [Abstract][Full Text] [Related]